Nucleus Accumbens Cholinergic Activity Rises During the Dark Cycle
The nucleus accumbens does not sit still across the day. In male rodents, spontaneous firing of cholinergic interneurons varied across the light-dark cycle, with a clear increase during the dark period, when reward seeking and exploratory behavior are typically more active in nocturnal species. This pattern places local acetylcholine signaling in step with the brain’s broader circadian organization rather than treating the accumbens as a static reward relay.
Cholinergic interneurons are the principal source of acetylcholine in this region, and their influence extends well beyond a simple tonic signal. They regulate dopamine release through nicotinic acetylcholine receptors on local terminals, meaning a shift in interneuron firing can change the timing and magnitude of dopaminergic output. In practical neurobiological terms, the same circuitry that supports reward processing also appears to be tuned by time of day.
One result stood out immediately: firing was not uniform across conditions. The dark cycle carried higher baseline spontaneous activity, suggesting that endogenous accumbal cholinergic tone is not constant but instead follows a rhythmic pattern capable of shaping downstream dopamine dynamics.
Nicotinic Receptor Modulation Diverges by Time of Day
Investigators used ex vivo fast-scan cyclic voltammetry and cell-attached electrophysiological recordings to probe how nicotinic receptor manipulation altered this circuit. They examined the effects of nicotine, mecamylamine, and dihydro-β-erythroidine on spontaneous firing frequency and firing patterns, while also assessing nicotinic control of dopamine release. The central finding was not simply that these agents changed firing, but that the response depended on whether the tissue came from the light or dark cycle.
During the dark cycle, all three compounds reduced firing frequency. In the light cycle, only mecamylamine decreased firing frequency. That split suggests receptor engagement is not uniform across the circadian cycle, and it points to a state-dependent cholinergic system whose responsiveness changes with internal time. The difference is pharmacologically important: a receptor antagonist can behave differently depending on the baseline network state it encounters.
Mecamylamine also altered firing patterns during the dark cycle, while dihydro-β-erythroidine mainly affected firing frequency. Nicotine joined mecamylamine in changing firing patterns during the dark cycle as well. Those distinctions imply that more than one nicotinic mechanism is operating on these neurons, and that receptor subtype or receptor availability may vary across the day.
Acetylcholine and Dopamine Are Likely Coupled to Circadian Reward State
The biology fits with what is known about the accumbens. This structure helps regulate motivated behavior, reinforcement learning, and reward-related responses, all of which fluctuate with circadian phase. If cholinergic interneurons fire more during the dark cycle, they may help set a permissive state for dopamine signaling at precisely the time when nocturnal animals are most behaviorally engaged. A circadian increase in acetylcholine could sharpen phasic dopaminergic responses, alter synaptic gain, and change the salience of reward-predictive cues.
That mechanism matters because nicotinic receptors sit at the intersection of endogenous circuit control and drug exposure. Nicotine does not act on a blank neural slate; it acts on a system already shaped by time of day. In a reward circuit such as the nucleus accumbens, a diurnal difference in receptor-dependent inhibition or excitation could influence how strongly the network responds to both natural rewards and nicotine itself.
The findings also fit with the broader idea that diurnal biology extends into limbic circuitry. Sleep-wake state, light exposure, and intrinsic circadian clocks all influence neurotransmission. Here, the cholinergic system appears to be embedded in that temporal architecture, with spontaneous interneuron activity and receptor responsiveness both varying across the light-dark cycle.
Why the Dark Cycle Response Looks Stronger
The stronger dark-cycle effects may reflect a network that is already primed for higher activity. When baseline firing is elevated, nicotinic receptor modulation may have a larger functional impact on membrane excitability or pattern generation. In contrast, the light cycle may represent a lower-activity state in which fewer nicotinic manipulations can push the system far enough to change firing frequency measurably.
Another plausible explanation involves receptor accessibility or downstream coupling. Nicotinic receptor signaling can shape firing through rapid depolarizing effects, desensitization, and feedback within local microcircuits. If receptor composition or endogenous acetylcholine release shifts by time of day, the same pharmacologic intervention would not be expected to produce identical results across circadian phases.
The abstract does not provide evidence for mechanism beyond these functional observations, and it does not establish which molecular clock components drive the pattern. Even so, the physiological signal is strong enough to suggest that the accumbens cholinergic system is under circadian control and that this control is expressed at the level of neuronal firing.
Implications for Reward Circuit Timing and Nicotine Biology
Because the nucleus accumbens sits at the center of reward-related behavior, time-of-day variation in its cholinergic tone may matter for several downstream processes. It may help explain why motivated behavior, cue reactivity, and drug responsiveness fluctuate over a 24-hour cycle. It may also inform how nicotine interacts with reward circuitry, since the same receptors targeted by nicotine show altered functional consequences depending on circadian phase.
The study is preclinical and restricted to male rodents, so it cannot be assumed to generalize to females or to humans without further work. The experiments were ex vivo as well, which means they isolate local circuit physiology rather than capturing the full influence of ongoing behavior, endocrine state, or systemic circadian inputs. Even so, the design is well suited to one question: whether the cholinergic machinery of the nucleus accumbens follows a daily rhythm. It does.
That leaves a clinically relevant gap rather than a tidy conclusion. The next questions are how this rhythm relates to behavior, whether it differs by sex, and whether chronic nicotine exposure or circadian disruption amplifies the effect. Those are the variables that will determine how far a time-dependent accumbens signal can be carried from slice physiology into disease biology.